January 22nd, 2012, by David Pascoe | clinical trials, galderma, metrogel
A recently posted clinical trial suggests that Taro Pharmaceuticals is readying to gain approval to market Generic Metrogel 1%. Currently Generic Metrogel is only available in 0.75% strength. Taro Pharmaceuticals in fact already markets a generic form of Metrogel – Metronidazole Gel USP, 0.75% When the patent covering Metrogel 0.75% expired, Galderma changed the formulation, increased the concentration of metronidazole to 1% …
December 5th, 2011, by David Pascoe | clinical trials, finacea
Some recent trial results confirm that Intendis are moving forward with the development of Finacea Foam. The summary of a recent trial, quoted in Skin and Allergy News shows that Finacea Foam is more effective at reducing rosacea symptoms compared to the inactive vehicle. This trial doesn’t show whether Finacea Foam is more effective than Finacea Gel, but does suggest that Finacea Foam likely to …
October 14th, 2011, by David Pascoe | clinical trials, new treatments, red face
A product from Merck designated as MK-0524, also known as Laropiprant, is to be trialled as a treatment for the redness of rosacea. This is great news for rosacea …
October 7th, 2011, by David Pascoe | clinical trials
Writing in the British Journal of Dermatology, the well known Rosacea Researcher Professor Frank Powell says that research based on randomized clinical trials are not the be-all and end-all for rosacea research. He tells us that there is still room for other sorts of innovation, especially when seeking treatments from your dermatologist. Recently a Cochrane review of 58 clinical trials told us that …
September 21st, 2011, by David Pascoe | clinical trials, galderma, oracea
A recently posted proposed Clinical Trial has me thinking that Galderma wants to be able to market Oracea as a product to Maintain Rosacea Remission. First Some History …
